Replies to post #78575 on Biotech Values

[medchal]

There have been some possible problems reported recently with sulfur colloid, which is, by the way, not approved by the F. D. A. as currently used in locating sentinel lymph nodes. My semi-educated guess is that no hard sell will be necessary, for all the obvious reasons stemming from the above facts. (Sulfur colloid is not exactly given away, either.)

That being said, I'll let everyone do his own research on the subject and remind all that Lymphoseek is not yet approved and that Neoprobe is therefore subject to all the usual risks which that circumstance entails. I only intended my message as a heads up for any (like you) who might be casually watching the stock. I'm sure all the holders have already digested this new news release.

[deut8-18]

Cardinal Health has exclusive distributorship.

From link:http://finance.yahoo.com/news/Neoprobe-Announces-Positive-bw-15170343.html?.v=1
Lymphoseek identified 40 nodes that did not contain the vital blue dye. Of those 40 nodes, 19% were determined by pathology to contain tumor. None of the nodes that contained only vital blue dye were found to contain tumor. Two of Dr. Sondak’s patients experienced a serious adverse event (SAE), but neither of the SAEs was considered to be related to Lymphoseek.

Lymphoseek clears faster saving time also.
IV board: http://www.investorvillage.com/groups.asp?mb=16085
Blog:http://neopstock.blogspot.com/
Deut 8:18